ScholarIQanswers from OpenAlex & ORCID
Kathryn A. Gold
ResearcherPublications, citations & collaboration network
Kathryn A. Gold is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Kathryn A. Gold have?
ScholarIQindexed works
Kathryn A. Gold has 182 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Kathryn A. Gold have?
ScholarIQcitation count
Kathryn A. Gold has 7,085 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Kathryn A. Gold?
ScholarIQh-index
Kathryn A. Gold has an h-index of 34 in OpenAlex.
What is the i10-index of Kathryn A. Gold?
ScholarIQi10-index
Kathryn A. Gold has an i10-index of 70 in OpenAlex.
What is the ORCID of Kathryn A. Gold?
ScholarIQorcid
The ORCID for Kathryn A. Gold is on the source record.
What is the OpenAlex record for Kathryn A. Gold?
ScholarIQopenalex
The OpenAlex for Kathryn A. Gold is on the source record.
What are the most-cited papers on Kathryn A. Gold?
ScholarIQmost cited works
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Jianjun Zhang, Junya Fujimoto, Jianhua Zhang, David C. Wedge, Xingzhi Song, Jiexin Zhang, Sahil Seth, Chi‐Wan Chow, Yu Cao, Curtis Gumbs, Kathryn A. Gold, Neda Kalhor, Latasha Little, Harshad S. Mahadeshwar, César A. Moran, Alexei Protopopov, Huandong Sun, Jiabin Tang, Xifeng Wu, Yuanqing Ye, William N. William, J. Jack Lee, John V. Heymach, Waun Ki Hong, Stephen G. Swisher, Ignacio I. Wistuba, P. Andrew Futreal
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel, Gregory J. Riely, Jeremy Cetnar, Howard West, D. Ross Camidge, Mark A. Socinski, Alberto Chiappori, Tarek Mekhail, Bo H. Chao, Hossein Borghaei, Kathryn A. Gold, Ali Zeaiter, Walter Bordogna, Bogdana Balas, Óscar Puig, Volkmar Henschel, Sai‐Hong Ignatius Ou
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
James Chih‐Hsin Yang, Myung‐Ju Ahn, Dong‐Wan Kim, Suresh S. Ramalingam, Lecia V. Sequist, Wu‐Chou Su, Sang-We Kim, Joo-Hang Kim, David Planchard, Enriqueta Felip, Fiona Blackhall, Daniel Haggstrom, Kiyotaka Yoh, Silvia Novello, Kathryn A. Gold, Tomonori Hirashima, Chia‐Chi Lin, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Pasi A. Jänne
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck, Alexander Luft, Aleksandra Szczęsna, Libor Havel, Sang-We Kim, Wallace Akerley, M. Catherine Pietanza, Yi‐Long Wu, Christoph Zielinski, Michael J. Thomas, Enriqueta Felip, Kathryn A. Gold, Leora Horn, Joachim G.J.V. Aerts, Kazuhiko Nakagawa, Paul Lorigan, Anne Pieters, Teresa Kong Sanchez, Justin Fairchild, David R. Spigel
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Apar Kishor Ganti, Billy W. Loo, M. Bassetti, Collin M. Blakely, Anne C. Chiang, Thomas A. D’Amico, Christopher D’Avella, Afshin Dowlati, Robert J. Downey, Martin J. Edelman, Charles Florsheim, Kathryn A. Gold, Jonathan W. Goldman, J.C. Grecula, Christine L. Hann, Wade T. Iams, Puneeth Iyengar, Karen Kelly, Maya Khalil, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian R. Molina, César A. Moran, Saraswati Pokharel, Sonam Puri, Angel Qin, Chad G. Rusthoven, Jacob Sands, Rafael Santana-Dávila, Michael Shafique, Saiama N. Waqar, Kristina M. Gregory, Miranda Hughes